Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,587 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
Baert F, Glorieus E, Reenaers C, D'Haens G, Peeters H, Franchimont D, Dewit O, Caenepeel P, Louis E, Van Assche G; BIRD (Belgian IBD Research and Development). Baert F, et al. Among authors: louis e. J Crohns Colitis. 2013 Mar;7(2):154-60. doi: 10.1016/j.crohns.2012.03.018. Epub 2012 Apr 24. J Crohns Colitis. 2013. PMID: 22537637
Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up.
Baert F, Schmit A, D'Haens G, Dedeurwaerdere F, Louis E, Cabooter M, De Vos M, Fontaine F, Naegels S, Schurmans P, Stals H, Geboes K, Rutgeerts P; Belgian IBD Research Group; Codali Brussels. Baert F, et al. Among authors: louis e. Gastroenterology. 2002 Jan;122(1):20-5. doi: 10.1053/gast.2002.30295. Gastroenterology. 2002. PMID: 11781276 Clinical Trial.
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Vermeire S, et al. Among authors: louis e. Am J Gastroenterol. 2002 Sep;97(9):2357-63. doi: 10.1111/j.1572-0241.2002.05991.x. Am J Gastroenterol. 2002. PMID: 12358256 Free article.
The role of aminosalicylates in the treatment of ulcerative colitis.
Van Assche G, Baert F, De Reuck M, De Vos M, De Wit O, Hoang P, Louis E, Mana F, Pelckmans P, Rutgeerts P, Van Gossum A, D'Haens G. Van Assche G, et al. Among authors: louis e. Acta Gastroenterol Belg. 2002 Oct-Dec;65(4):196-9. Acta Gastroenterol Belg. 2002. PMID: 12619425
Immunogenicity of infliximab: how to handle the problem?
Baert F, De Vos M, Louis E, Vermeire S; Belgian IBD Research Group. Baert F, et al. Among authors: louis e. Acta Gastroenterol Belg. 2007 Apr-Jun;70(2):163-70. Acta Gastroenterol Belg. 2007. PMID: 17715629 Review.
Clinical and genetic factors associated with sacroiliitis in Crohn's disease.
Peeters H, Vander Cruyssen B, Mielants H, de Vlam K, Vermeire S, Louis E, Rutgeerts P, Belaiche J, De Vos M. Peeters H, et al. Among authors: louis e. J Gastroenterol Hepatol. 2008 Jan;23(1):132-7. doi: 10.1111/j.1440-1746.2007.05108.x. Epub 2007 Aug 27. J Gastroenterol Hepatol. 2008. PMID: 17725592 Free article.
Does the behavior of Crohn's disease change over time?
Louis E, Reenaers C, Belaiche J. Louis E, et al. Inflamm Bowel Dis. 2008 Oct;14 Suppl 2:S54-5. doi: 10.1002/ibd.20561. Inflamm Bowel Dis. 2008. PMID: 18816690 Free article. No abstract available.
1,587 results